Only Taejoon’s succeeds in avoiding Simbrinza’s patent

Taejoon’s is the only generic company to succeed in avoiding Novartis’ composition patent

Wins first trial against Novartis… prepares foothold for early release of its generic

Taejoon Pharmaceutical succeeds in avoiding the patent for Novartis’s glaucoma treatment ‘Simbrinza eyedrops (brimonidine+ brinzolamide).’ Being the only company to successfully avoid Novartis’s patent, Taejoon Pharmaceutical will now be able to develop a generic version of Simbrinza Eye Drops in a relatively relaxed manner.

 

According to industry sources on the 30th, Taejoon Pharmaceutical recently won the Passive Trial to Confirm the Scope of Patent Rights it filed against the composition patent of Novartis’ Simbrinza Eye Drops.

 

Taejoon Pharmaceutical had filed the suit in July last year, and this is the only patent registered in Korea for Simbrinza Eye Drops.

 

The patent will expire by June 2030, and its PMS has expired in June this year.

 

With the victory, Taejoon Pharmaceutical prepared a foothold for the early release of its Simbrinza generic.

 

If Taejoon Pharmaceutical succeeds in developing its generic and receives marketing approval, the company may immediately release its product.

 

Currently Taejoon Pharmaceutical is the only company to succeed in avoiding its patent.

 

Originally, Chong Kun Dang had challenged the patent with Taejoon Pharmaceutical, however, CKD had dropped its suit, and Taejoon continued on its challenge by itself.

 

With no generic competitor, the company will be able to continue developing its generic in a relatively easier manner.

 

Taejoon Pharmaceutical is currently selling other glaucoma treatments in the market.

 

Its Xalost Eye Drops (latanoprost)’ is a generic of Pfizer’s ‘Xalatan Eye Drop,’ and its ‘Combisopt Eye Drops (timolol+dorzolamide’ is a generic of Santen Pham Korea’s ‘Cosopt Eye Drops.’ Taejoon Pharmaceutical plans to bring synergy into the glaucoma treatment market by adding a Simbrinza generic to its portfolio.

 

According to the pharmaceutical market research institution IQVIA, its Xalost sold 6.5 billion won and Combisopt sold 0.2 bill won last year.

 

Simbrinza Eye Drops have steadily sold around 2 billion won annually.

 

The product has recorded 1.1 billion won in sales in the first half of this year.